^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Glioma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

    Excerpt:
    ...Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated sequencing technique (result does...
    Trial ID:
    DETERMINE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neurology
    Title:

    Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

    Published date:
    06/04/2021
    Excerpt:
    Twenty-eight adults with recurrent or disseminated BRAF V600-mutant gangliogliomas (n=9), pleomorphic xanthoastrocytomas (n=9), and diffuse gliomas...15 combinations of RAFi/MEKi [vemurafenib+cobimetinib (n=5), dabrafenib+trametinib...Eleven patients achieved a partial or complete response (11/28, 39%), with a median reduction of -78% in their tumor burden....Five patients were rechallenged with RAFi/MEKi at progression, with novel tumor responses in two....study highlights the clinical benefits of RAFi/MEKi in adult patients with BRAF-mutant GGNT...
    DOI:
    https://doi.org/10.1212/WNL.0000000000012330